Regulatory press release03.12.2025, 18.55Lipigon Pharmaceuticals presents top-line data from the Phase II clinical trial of Lipisense in patients with elevated blood lipid levels
Press release14.10.2025, 22.58Lipigon Pharmaceuticals reports last patient visit in the three-month follow-up of its Phase II clinical study with Lipisense
Regulatory press release06.07.2025, 09.03Lipigon Pharmaceuticals Enrolls Last Patient in Phase II Study with Lipisense®
Regulatory press release20.03.2025, 12.15Lipigon Pharmaceuticals' commercial partner announces positive results from Phase I clinical trial with Lipisense
Regulatory press release21.11.2024, 10.00Första patienten doserad i Lipigon Pharmaceuticals kliniska fas II-studie med Lipisense®
Press release18.09.2024, 12.51Lipigon's development partner Leaderna Therapeutics reports last person treated in ongoing Phase 1 study with Lipisense®
Regulatory press release09.07.2024, 14.00Lipigon Receives Milestone Payment of USD 1 Million from Leaderna for Approval of Phase I Bridging Study
Press release20.06.2024, 08.30New Publication: The ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes
Regulatory press release14.05.2024, 07.53Lipigon collaborates with University of Washington on lung damage project
Press release07.02.2024, 16.00The Swedish Medical Products Agency approves Lipigon's phase II study with Lipisense®